An NOAC based strategy has lower bleeding risk compared to a VKA- based strategy. 29. In AF patients in which aspirin is concomitantly used with OAC, we suggest a dose of 75-100 mg qd with concomitant use of PPI to minimize gastrointestinal bleeding (Weak recommendation, low quality evidence). 30. In AF patients in which a P2Y12 inhibitor is concomitantly used with OAC, we suggest the use of clopidogrel (Weak recommendation, low quality evidence). Remark: Newer agents (eg, ticagrelor) can be considered where bleeding risk is low. Data on the combination of ticagrelor with either dabigatran 110 mg bid or 150 bid (without concomitant aspirin use) are available from the RE-DUAL PCI trial. *31. For patients with AF and stable coronary artery disease (eg, no acute coronary syndrome within the previous year) and who choose oral anticoagulation, we suggest OAC with either an NOAC or adjusted- dose VKA therapy alone (target international normalized ratio [INR] range, 2.0-3.0) rather than the combination of OAC and aspirin (Weak recommendation, low quality evidence). 32. In patients with AF in whom catheter ablation of AF or implantation of cardiac electronic implantable devices is planned, we suggest performing the procedure on uninterrupted VKA (within the INR therapeutic range), dabigatran or rivaroxaban (Weak recommendation, low quality evidence). 33. In patients in whom sinus rhythm has been restored, we suggest that long-term anticoagulation should be based on the patient s CHA2DS2-VASc thromboembolic risk pro le, regardless of whether sinus rhythm has been restored via ablation, cardioversion (even spontaneous), or other means (Weak recommendation, low quality evidence). 34. In AF patients with acute ischemic stroke, we suggest that very early anticoagulation (< 48 h) using heparinoids or VKA should not be used (Ungraded consensus-based statement). 